imaGeneBio
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12526 High Bluff Dr Ste 345, San Diego, ...Website
www.imagenebio.comRevenue
-Stock Symbol
IMAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About imaGeneBio
ImageneBio, Inc. is a global clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company is dedicated to advancing differentiated treatment approaches that target key immune pathways involved in T cell activation and inflammatory disease progression. ImageneBio's pipeline is designed to address conditions with significant unmet medical need, including atopic dermatitis and alopecia areata. ImageneBio trades on the NASDAQ under the ticker symbol IMA.Explore more
imaGeneBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is imaGeneBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once imaGeneBio has new funding data
Earning: See what the market has to say on imaGeneBio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if imaGeneBio has recently received funding, and reach out quickly before it becomes old news!
imaGeneBio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if imaGeneBio had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at imaGeneBio
Check out if imaGeneBio is spiking on competitors!
Product Launch: Get notified when imaGeneBio launches new products
Recommended Actions
Reach out to Masked Content who joined imaGeneBio as Masked Content
Find 3 more new buyers
Compare Similar Companies to imaGeneBio
Compare insights from companies similar to imaGeneBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
imaGeneBio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
imaGeneBio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about imaGeneBio.
imaGeneBio Tech Stack
A closer look at the technologies used by imaGeneBio
See more technologies
Most Recent Scoops
Project
imaGeneBio has engineered IMG-007 with an extended half-life of approximately 35 days, enabling potentially quarterly or longer dosing intervals and opening the possibility of treatment discontinuation for patients achieving low disease activity or remission.
Medical Research, Pharmaceuticals
Project
imaGeneBio has incorporated Fc silencing engineering into IMG-007 to make it T cell preserving and non-depleting, supporting a better safety profile and enabling dose escalation and therapeutic index exploration.
Engineering
Project
imaGeneBio has initiated a Phase IIB adaptive study for atopic dermatitis, featuring four active arms and one placebo arm across doses of 300 mg and 600 mg at Q12 and Q4 weekly intervals, with a primary endpoint at 24 weeks, continuous treatment through 48 weeks, and top-line data anticipated in Q4 2027. The study is currently active in the US and Canada, with Europe and additional countries to be added in the coming months.
Medical Research, Pharmaceuticals, Clinical Operations
Project
imaGeneBio has completed a proof-of-concept study of IMG-007 in atopic dermatitis involving 13 patients, in which 54% of patients achieved EASI-75 and approximately one-third achieved EASI-90 at 16 weeks, with no serious adverse events, no treatment-related adverse events, and biomarker data demonstrating pan-pathway normalization of Th1, Th2, and Th17 serum proteins.
Proof of Concept (POC), Medical Research
Project
Proof of Concept (POC), Medical Research
imaGeneBio News & Media
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life.ImageneBio Announces $30 Million Private Placement
SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA)(“Imagene” or the “Company”) today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million to Imagene, before deducting placement agent fees and other expenses. The company intends to use the proceeds from the offering to support further development of IMG-007 in alopeciaImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on March 16, 2026 the Company’s Compensation Committee of the Board of Directors (the “Compensation Committee”) granted equity awards to two newly hired employees in the form of restricted stock units (“RSUs”) and non-qualified stock options (“NSOs”) for an aggregate of 38,442 RSUs and 43,000 NSOs as an inducement material to their acceptance of employment withImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding imaGeneBio
Sign Up For FreeTo access detailed company insights
ImageneBio, Inc. is a global clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutics for patients with immunological, autoimmune, and inflammatory diseases. The company is dedicated to advancing differentiated treatment approaches that target key immune pathways involved in T cell activa... Read More
